| Revenue growth | 17% CAGR (FY11-FY26); FY26 sales Rs 582 Bn. |
|---|---|
| Margins | EBITDA margin improved from 26.9% (FY22) to 30.3% (FY26). |
| Demand visibility | Strong across chronic segments and Innovative Medicines portfolio. |
| Management confidence | High; citing 'Strong balance sheet' and 'Best-in-class profitability'. |
Growth
FY26 sales reached Rs 582 Bn, with a CAGR of 17% (FY11-FY26). EBITDA margin expanded to 30.3% in FY26.
Outlook
Targeting increased contribution from Innovative Medicines and complex products. R&D investment stands at 6.1% of sales.
Risks
Exposure to US generics market dynamics and ongoing global regulatory compliance across 40 manufacturing facilities.
Last quarter's promises, checked
Delivered
- High single-digit FY27 revenue growth → delivered 10.1% Q1 growth (= BEAT)
- Organon closing by early 2027 → on track with shareholder approval (= BEAT)
- Innovative medicine growth → delivered $351M, up 12.8% (= BEAT)
Partly delivered
- R&D spend normalization → Q1 tracking lower at 5.4% of sales (= PARTIAL)
Missed
- EBITDA margin improvement → delivered 28.9% vs higher FY26 base (= MISS)
Investor Presentation filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,804.10
- Market cap
- ₹4,32,864 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 54.48%+0.00% QoQ
- FII holding
- 14.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Promoter Reclassification
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharmaceutical Industries Legal & Regulatory
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharmaceutical Industries Merger & Restructuring Worth ₹9.5 Cr
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
- Value
- ₹9.50 Cr
Sun Pharmaceutical Industries Credit Rating
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharmaceutical Industries Business Update
Sun Pharma attended a White House signing ceremony, committing to Most Favored Nation pricing for U.S. Medicaid programs and future innovative medicine launches.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma seeks shareholder approval via postal ballot to reclassify three members of the 'Promoter Group' to the 'Public' category, effective upon requisite approval.